Global Research Collaboration for Infectious Disease Preparedness

Global Research Collaboration for Infectious Disease Preparedness
Name	Global Research Collaboration for Infectious Disease Preparedness
Abbreviation	GRCIDP
Formation	2018
Type	International research consortium
Headquarters	Geneva
Region served	Global
Leader title	Chair
Leader name	Maria Van Kerkhove
Website	(not provided)

Global Research Collaboration for Infectious Disease Preparedness is an international consortium formed to coordinate scientific research, surveillance, and response to emerging infectious diseases, aiming to accelerate development of diagnostics, therapeutics, and vaccines. It links public health agencies, academic institutions, philanthropic funders, and multilateral organizations to harmonize protocols, share data, and prioritize research gaps during epidemics and pandemics.

Background and Rationale

The initiative emerged amid heightened attention after the 2014 West Africa Ebola virus epidemic, the 2016 Zika virus epidemic, and the COVID-19 pandemic, when coordination deficits among World Health Organization, Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, National Institutes of Health, and national research bodies impeded rapid evidence generation. Influenced by frameworks such as the International Health Regulations (2005), the consortium sought to integrate capabilities from Wellcome Trust, Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Gavi, the Vaccine Alliance, and academic hubs including Johns Hopkins University, Imperial College London, Karolinska Institutet, and University of Oxford to reduce duplication and expedite countermeasure evaluation. Lessons from responses led by Médecins Sans Frontières, Centers for Disease Control and Prevention (Nigeria), Public Health England, and national research institutes highlighted the need for pre-established research platforms and legal agreements among African Union, European Union, Association of Southeast Asian Nations, and regional health networks.

International Governance and Coordination Mechanisms

Governance models draw on precedents from United Nations, World Bank, Global Health Security Agenda, and the Access to COVID-19 Tools Accelerator, embedding steering committees with representatives from World Health Organization, Pan American Health Organization, Africa Centres for Disease Control and Prevention, Asian Development Bank, and philanthropic partners. Memoranda of understanding and legal templates reference Nagoya Protocol considerations and coordinate with national authorities such as Ministry of Health (Brazil), National Health Commission (China), and Ministry of Health and Family Welfare (India), while expert advisory groups include members from Royal Society, National Academy of Sciences, Academia Sinica, and specialist networks like Coalition for Epidemic Preparedness Innovations Scientific Advisory Board. The governance structure balances rapid decision-making during outbreaks with oversight from institutional review boards affiliated with Harvard T.H. Chan School of Public Health, Peking University Health Science Center, and Pasteur Institute.

Research Networks and Data Sharing Infrastructure

Research platforms build on trial networks such as International Severe Acute Respiratory and Emerging Infection Consortium, ISARIC, REMAP-CAP, SOLIDARITY Trial, and consortia including Global Influenza Surveillance and Response System, linking laboratories like Centers for Disease Control and Prevention (United States), China CDC, Institut Pasteur, KEMRI–Wellcome Trust Research Programme, and National Institute for Communicable Diseases (South Africa). Data sharing leverages standards from FAIR data principles and tools developed by European Bioinformatics Institute, National Center for Biotechnology Information, Global Initiative on Sharing All Influenza Data, and Open Data Institute, with secure platforms modeled on systems used by ClinicalTrials.gov and European Medicines Agency. Cross-border sample transfer and genomic surveillance coordinate with networks such as Nextstrain and collaborations among Wellcome Sanger Institute, Broad Institute, and regional reference labs.

Funding Models and Resource Allocation

Financing integrates multilateral funding from entities like World Bank Pandemic Fund, philanthropic grants from Bill & Melinda Gates Foundation and Wellcome Trust, bilateral aid from United States Agency for International Development, Foreign, Commonwealth & Development Office (UK), and pooled mechanisms similar to Global Fund to Fight AIDS, Tuberculosis and Malaria. Resource allocation employs priority-setting methods informed by agencies such as WHO Research and Development Blueprint, National Institutes of Health, and European Commission Horizon 2020 experience, with rapid-release contingency funds modeled on emergency financing used by Global Fund and reprogrammable grants administered by UNICEF procurement systems. Public–private partnerships emulate arrangements between AstraZeneca, Pfizer, Moderna, and global procurement mechanisms coordinated by Gavi.

Capacity Building and Technology Transfer

Capacity efforts coordinate training and infrastructure investments with partners including Africa CDC Institute for Workforce Development, London School of Hygiene & Tropical Medicine, Scripps Research Institute, Institut Pasteur de Dakar, and Makerere University. Technology transfer and manufacturing scale-up draw lessons from collaborations involving BioNTech, Serum Institute of India, Sinovac, and regional vaccine production initiatives supported by African Union and Pan American Health Organization. Laboratory strengthening aligns with accreditation frameworks from College of American Pathologists and biosafety standards referencing World Organisation for Animal Health and European Centre for Disease Prevention and Control guidance.

Ethical, Legal, and Social Considerations

Ethical frameworks reference guidelines from Declaration of Helsinki, Council for International Organizations of Medical Sciences, and institutional review boards at Yale School of Medicine and University of Cape Town Faculty of Health Sciences, addressing informed consent, benefit-sharing under the Nagoya Protocol, data privacy complying with General Data Protection Regulation requirements, and equitable access principles advocated by Just Security and Doctors Without Borders. Legal instruments negotiate intellectual property pathways inspired by TRIPS Agreement flexibilities and voluntary licensing precedents such as the Medicines Patent Pool.

Case Studies and Lessons Learned from Past Outbreaks

Case studies draw on responses to the 2014 West Africa Ebola virus epidemic, the 2016 Zika virus epidemic, the 2019–20 COVID-19 pandemic, and the 2009 swine flu pandemic, highlighting successes of coordinated trials like SOLIDARITY Trial and challenges observed during supply-chain disruptions affecting Personal Protective Equipment procurement sourced through partnerships with UNICEF and WHO Supply Chain. Analyses reference modelling and policy work from Imperial College London, Johns Hopkins Center for Health Security, Lancet Infectious Diseases, and operational lessons from Médecins Sans Frontières deployments, underscoring the need for sustained financing, interoperable data systems, and pre-established legal arrangements among Sovereign States and international organizations.

Category:International medical and health organizations